For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/management-approaches-for-eoe-9991

Summary
The American College of Gastroenterology has published the first new guidelines for the treatment of eosinophilic esophagitis (EoE) since 2013. In this CME/CE podcast, Drs. Paul Feuerstadt and Brooks Cash discuss these latest recommendations, reviewing the role of proton pump inhibitors, topical steroids, diet elimination, a biologic, and esophageal dilation in the management of this increasingly recognized condition.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Assess the efficacy and safety profile of approved agents for EoE, with a focus on swallowed corticosteroids, in the management of EoE
• Apply evidence-based guidelines to optimize treatment outcomes and improve the quality of life for patients with EoE

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Send us a text about this episode.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/on-the-lookout-for-eoe-9990

Summary
In this CME/CE podcast, two gastroenterologists discuss the increasing prevalence of eosinophilic esophagitis (EoE), our evolving understanding of its pathophysiology, and its varied clinical presentation. Drs. Brooks Cash and Paul Feuerstadt also review the need for early identification of the condition, and discuss the latest American College of Gastroenterology guideline for diagnosis.

Learning Objective
At the conclusion of this activity, participants should be better able to:

• Identify common clinical presentations and diagnostic challenges to facilitate early diagnosis of EoE in diverse patient populations

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Send us a text about this episode.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/psychedelics-for-depression-9984

Summary
In this PsychTalk podcast/webcast episode, Drs. Gregory Mattingly and Gerald Maguire explore the emerging role of psychedelics in treating mental health conditions. Listeners will learn about the mechanisms of action of psychedelic therapeutics and gain insights into their effects on the brain and behavior. The program will also review recent clinical trial data on the efficacy of psychedelic treatments for major depressive disorder (MDD), as well as provide expert insights on how to discuss the future of psychedelics with patients.

This podcast was recorded and is being used with permission of the presenters.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Describe the mechanism of action of psychedelic therapeutics
• Review clinical trial data regarding the use of psychedelic treatments in MDD

This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.75 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is not commercially supported.

Send us a text about this episode.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.